Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Zarzio |
|---|---|
| Manufacturer | Sandoz Inc |
| Prescription required | Yes |
Zarzio 48MU/0.5ml jeringas 5 x 0.5m (filgrastim)
filgrastim
Description
Zarzio 48MU/0.5ml jeringas 5 x 0.5m (filgrastim) is a medicine catalog record in the MediPriceHub database. Active ingredient: filgrastim. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Sandoz Inc. Therapeutic category: Medicine Library > Oncology Medicines > Chemotherapy drugs. Pack information: 48 / 0.5, 5 x 0.5. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need fHow to Use
Use filgrastim under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: filgrastim. Pack size: 48 / 0.5, 5 x 0.5. Pack unit: box. Manufacturer: Sandoz Inc. Origin country: Spain. Source category: Medicine Library > Oncology Medicines > Chemotherapy drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.